The ADAPT study showed that neoadjuvant therapy with 12 weeks of trastuzumab emtansine with or without endocrine therapy, or with 12 weeks of trastuzumab plus endocrine therapy resulted in a tpCR rate of 41.0%, 41.5%, and 15.1% in patients with HR‐positive, HER2‐positive early breast cancer,34 respectively. This evidence concerns the gene ERBB2 and breast carcinoma.